Q3 EPS Estimate for Capricor Therapeutics Cut by Analyst

Capricor Therapeutics, Inc. (NASDAQ:CAPR) – Equities research analysts at HC Wainwright decreased their Q3 2026 EPS estimates for Capricor Therapeutics in a research note issued on Friday, August 14th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will post earnings per share of ($0.73) for the quarter, down from their prior estimate of ($0.63). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.62) per share. HC Wainwright also issued estimates for Capricor Therapeutics’ Q4 2026 earnings at ($0.73) EPS, FY2026 earnings at ($2.75) EPS and FY2027 earnings at ($2.84) EPS.

A number of other research analysts have also weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Monday, June 15th. Roth Capital downgraded Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 price target for the company. in a report on Monday, July 27th. Oppenheimer reissued a “market perform” rating on shares of Capricor Therapeutics in a research report on Monday, July 27th. Wall Street Zen cut Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. Finally, B. Riley Financial downgraded shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $10.00 price objective on the stock. in a report on Monday, July 27th. One research analyst has rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $29.15.

Capricor Therapeutics Stock Performance

CAPR stock opened at $7.45 on Tuesday. The business has a 50-day simple moving average of $17.81 and a two-hundred day simple moving average of $25.28. The company has a market capitalization of $431.43 million, a P/E ratio of -3.04 and a beta of 0.54. Capricor Therapeutics has a 52-week low of $2.96 and a 52-week high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Friday, August 14th. The biotechnology company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.11).

Insider Buying and Selling at Capricor Therapeutics

In other news, CFO Anthony Bergmann sold 24,100 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $30.38, for a total value of $732,158.00. Following the transaction, the chief financial officer owned 11,223 shares in the company, valued at $340,954.74. The trade was a 68.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders sold 25,000 shares of company stock valued at $759,158. 9.20% of the stock is owned by insiders.

Institutional Trading of Capricor Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Suvretta Capital Management LLC bought a new stake in Capricor Therapeutics during the fourth quarter worth $51,533,000. Tang Capital Management LLC bought a new position in Capricor Therapeutics in the 4th quarter valued at $49,062,000. RA Capital Management L.P. bought a new position in Capricor Therapeutics in the 4th quarter valued at $43,516,000. Darwin Global Management Ltd. purchased a new stake in shares of Capricor Therapeutics during the 4th quarter valued at $23,168,000. Finally, SB Capital Management Inc purchased a new stake in shares of Capricor Therapeutics during the 4th quarter valued at $11,544,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics News Summary

Here are the key news stories impacting Capricor Therapeutics this week:

• Negative Sentiment: A securities-fraud class action has been filed against Capricor and certain executives. The lawsuit alleges that the company made material misstatements or omissions about Deramiocel, the HOPE-3 clinical trial’s statistical analysis plan, FDA compliance, and the integrity of data supporting its Biologics License Application. The allegations relate to a previously reported 64% stock decline; they have not been proven in court. Capricor securities-fraud lawsuit
• Negative Sentiment: Multiple law firms are publicizing the class action and urging investors who purchased CAPR shares between December 17, 2025, and July 26, 2026, to seek lead-plaintiff status by late September. The repeated litigation notices may keep legal and clinical-data concerns in focus, potentially limiting buying interest. Capricor class-action deadline
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across several periods while maintaining a Neutral rating. Estimates were reduced to losses of $0.73 per share for both the third and fourth quarters of 2026, $2.75 for fiscal 2026, and $2.84 for fiscal 2027, from prior forecasts of $0.63, $0.60, $2.43, and $2.57, respectively. The revisions reinforce expectations for sustained cash burn and larger losses. HC Wainwright Capricor estimates
• Neutral Sentiment: Investor concerns were also amplified by reports that Capricor’s recent second-quarter earnings call did not include a management question-and-answer session with analysts, reducing near-term clarity on the company’s clinical, regulatory, and financing outlook. Capricor Q2 earnings and lawsuit update

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.